Skip to main content
Liaoning Cheng Da Co.,Ltd. logo

Liaoning Cheng Da Co.,Ltd. — Investor Relations & Filings

Ticker · 600739 ISIN · CNE000000LY3 LEI · 300300ZCCWKNUJRL8D79 Shanghai Stock Exchange Financial and insurance activities
Open in API
Filings indexed 2,288 across all filing types
Latest filing 2020-05-08 Capital/Financing Update
Country CN China
Listing Shanghai Stock Exchange 600739

About Liaoning Cheng Da Co.,Ltd.

https://en.chengda.com.cn/

Liaoning Cheng Da Co., Ltd. is a diversified conglomerate operating across several strategic sectors, including biopharmaceuticals, financial services, energy development, and international trade. The company is a prominent player in the biopharmaceutical field through its specialized subsidiaries, focusing on the research, development, and production of human vaccines, most notably its market-leading purified Vero cell rabies vaccine. In the energy sector, it engages in the extraction and processing of oil shale. Its financial services division involves significant investments in securities firms and insurance companies. Additionally, the company maintains a robust international trade business, dealing in commodities such as textiles and chemicals. Liaoning Cheng Da focuses on integrating industrial operations with financial capital to drive growth across its various business units.

Recent filings

Filing Released Lang Actions
董事会关于评估机构的独立性、评估假设前提的合理性、评估方法与评估目的的相关性以及评估定价的公允性的意见
Capital/Financing Update Classification · 95% confidence The document is a statement from the board of directors of 辽宁成大股份有限公司 regarding the independence, assumptions, methods, and fairness of an asset valuation report prepared by an appraisal firm for a transaction involving the sale of 100% equity in a subsidiary. It discusses the evaluation process and fairness of pricing but does not contain financial statements or detailed financial results. The document is an opinion or announcement related to an asset valuation for a capital transaction rather than a full financial report or audit. It is not a full Annual Report, Interim Report, or Audit Report. It is also not a simple announcement of a report publication but a substantive board opinion on the valuation. Given the content focuses on the evaluation related to a capital transaction, the best fitting category is Capital/Financing Update (CAP). The document length is short (1027 characters), but it contains substantive content about the valuation and transaction, not just a notice or certification. Therefore, classification as CAP is appropriate with high confidence.
2020-05-08 Chinese
关于公司所属子公司辽宁成大生物股份有限公司首次公开发行股票并在科创板上市申请获上海证券交易所受理的公告
Regulatory Filings Classification · 95% confidence The document is an announcement regarding the acceptance of the application for the initial public offering (IPO) and listing of a subsidiary company on the Shanghai Stock Exchange's STAR Market. It mentions receipt of the acceptance notice from the exchange and references the need for further approvals. The document is short (731 characters) and serves as a formal announcement of a regulatory event related to capital markets, specifically the IPO application acceptance. It does not contain financial statements, detailed financial data, or management discussion. It is not a full report but an announcement of a regulatory filing event. Therefore, the most appropriate classification is Regulatory Filings (RNS).
2020-05-08 Chinese
第九届监事会第十三次会议决议公告
Board/Management Information Classification · 95% confidence The document is a resolution announcement from the Supervisory Board of Liaoning Chengda Co., Ltd. regarding a decision made in a board meeting about the transfer of company assets. It includes details about the meeting date, attendance, and voting results. The content is about board/management decisions and does not contain financial statements or detailed financial data. It is not an annual report, audit report, or earnings release. It is not a regulatory filing or announcement of a report publication. The document fits best under Board/Management Information (MANG) as it announces a board resolution and related management decisions.
2020-05-08 Chinese
独立董事关于第九届董事会第十九次（临时）会议相关事项的独立意见
Regulatory Filings Classification · 95% confidence The document is an independent director's opinion regarding a specific transaction involving the transfer of company-held equity. It references a board meeting and legal compliance but does not contain financial statements or detailed financial data. The document is short (744 characters) and focuses on approval and opinion on a transaction rather than reporting financial results or detailed disclosures. This fits best under Regulatory Filings (RNS), as it is a regulatory announcement related to corporate governance and transaction approval, not a full report or financial statement.
2020-05-08 Chinese
第九届董事会第十八次（临时）会议决议公告
Board/Management Information Classification · 95% confidence The document is a board meeting resolution announcement from Liaoning Chengda Co., Ltd., detailing decisions made at the 18th interim meeting of the 9th board of directors. It includes approval of the company's Q1 2020 report, changes in accounting policies, revisions to board committee rules, and adjustments to board committee members. The document is an official announcement of board/management decisions and changes, not the full report itself. It is relatively short (971 characters) and serves as a formal disclosure of board resolutions, fitting the category of Board/Management Information (MANG).
2020-04-29 Chinese
关于会计政策变更的公告
Regulatory Filings Classification · 95% confidence The document is an announcement regarding a change in accounting policy by the company 辽宁成大股份有限公司. It discusses the adoption of a new revenue recognition standard effective from January 1, 2020, as required by the Ministry of Finance. The document includes opinions from independent directors and the supervisory board confirming the appropriateness and compliance of the change. The text is relatively short (1180 characters) and serves as a formal announcement rather than a full financial report or detailed audit. It does not contain comprehensive financial statements or detailed financial analysis. Therefore, it is best classified as a Regulatory Filing (RNS), which covers miscellaneous regulatory announcements that do not fit other specific categories.
2020-04-29 Chinese

Browse filings by year

27 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.